TY - JOUR T1 - International Union of Pharmacology. XXVIII. Proteinase-Activated Receptors JF - Pharmacological Reviews JO - Pharmacol Rev SP - 203 LP - 217 DO - 10.1124/pr.54.2.203 VL - 54 IS - 2 AU - Morley D. Hollenberg AU - Steven J. Compton Y1 - 2002/06/01 UR - http://pharmrev.aspetjournals.org/content/54/2/203.abstract N2 - Proteinase-activated receptors (PARs) represent a unique subclass of G-protein-coupled receptors of which four family members have now been cloned from a number of species. The novel mechanism of receptor activation involves the proteolytic unmasking of a cryptic N-terminal receptor sequence that, remaining tethered, binds to and triggers receptor function. In addition, short (five to six amino acids) synthetic peptides, based on the proteolytically revealed motif, can activate PARs without the unmasking of the tethered ligand. This article summarizes the experiments leading to the pharmacological characterization and cloning of the four PAR family members and provides a rationale for their designation by the acronym “PAR”. The ability to distinguish among the PARs pharmacologically 1) with selective proteinase activators, 2) with receptor-selective peptide agonists, and 3) with peptide and nonpeptide antagonists is discussed, as are the molecular mechanisms of receptor activation and desensitization/internalization. Finally, the potential physiological roles of the PARs, which are widely distributed in many organs in the settings of tissue injury, repair, and remodeling, including embryogenesis and oncogenesis are discussed, and the newly appreciated roles of proteinases as signaling molecules that can act as either functional agonists or antagonists are highlighted. ER -